Laddar populära aktier...
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding c...
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business...
- We cut '25e-'26e EBIT by 2%... - ...and still expect no organic growth in '24e - Trading at NTM EV...
- FTX claim sold and FlowBank investment impaired - We increase adj.
Redeye provides a research update following the Q3 report recently published by Newbury.
EU-lagen CRMA (European Critical Raw Materials Act) har blivit godkänd och gäller från och med mars ...
- Q2'24 results due 22 July - 24e-'26e EBIT revised down 1.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, som sjönk med 6% på årsb...
Redeye briefly comments on Enviro’s recent follow-up order for 500 tons of TPO from a leading Europe...
Inför Q2-rapporten räknar Analysguiden med en liknade utvecklingen som i det första kvartalet, med a...
Redeye comments on Invisio ahead of its Q2-results (due 19 July) where we expect strong growth drive...
Redeye comments on Freemelt ahead of its Q2 results, due on 6 August.
Redeye comments on Raketech’s divestment of its US high-touch tipster advisory business as it increa...
Redeye provides its initial comments on Nanologica following its Q2 report that showed softer sales ...
Ahead of Svedbergs Group's Q2 report on 18 July, we expect a decent quarter, with a 1% organic sales...